Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients

American Journal of Health-System Pharmacy

Volumn 66, Issue 19, 2009, Pages 1711-1717

  Menzin, Joseph ^a   Meyers, Juliana L ^a   Friedman, Mark ^a   Perfect, John R ^b   Langston, Amelia A ^c   Danna, Robert P ^d   Papadopoulos, George ^e  

^a Boston Health Economics Inc   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

^d META Associates LLC   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Costs; Epidemiology; Hospitals; Mortality; Mycoses

Indexed keywords

ADULT; AGED; ARTICLE; ASPERGILLOSIS; BLASTOMYCOSIS; BONE MARROW TRANSPLANTATION; CANDIDIASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COCCIDIAL INFECTION; CONTROLLED STUDY; CRYPTOCOCCOSIS; DIABETES MELLITUS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HISTOPLASMOSIS; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCORMYCOSIS; MYCOSIS; NEOPLASM; POPULATION RESEARCH; PRIORITY JOURNAL; UNITED STATES;

ADOLESCENT; ADULT; AGE FACTORS; AGED; FEMALE; HEALTH STATUS; HOSPITAL COSTS; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MYCOSES; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 70349754592     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080325     Document Type: Article

References (26)

1. Husain S, Alexander BD, Munoz P et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis. 2003; 37:221-229
2. Saiman L, Ludington E, Dawson JD et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J. 2001; 20:1119-1124 (Pubitemid 34016422)
3. Ellis M, Richardson M, de Pauw B. Epidemiology. Hosp Med. 2000; 61:605-609
4. Shulkin DJ, Anastasi LJ. Economic impact of infections in patients with cancer. Cancer Treat Res. 1998; 96:283-290
5. De Pauw BE, Meis JF. Progress in fighting systemic fungal infections in haematological neoplasia. Support Care Cancer. 1998; 6:31-38
6. Berghmans T, Crokaert F, Markiewicz E et al. Epidemiology of infections in the adult medical intensive care unit of a cancer hospital. Support Care Cancer. 1997; 5:234-240 (Pubitemid 27212874)
7. Wilson LS, Reyes CM, Stolpman M et al. The direct cost and incidence of systemic fungal infections. Value Health. 2002; 5:26-34. (Pubitemid 34160368)
8. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002; 34:7-14. (Pubitemid 33152659)
9. Pfaller MA. Epidemiology of candidiasis. J Hosp Infect. 1995; 30(suppl):329-338
10. Edmond MB, Wallace SE, McClish DK et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999; 29:239-244
11. Ullmann AJ, Cornely OA, Burchardt A et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother. 2006; 50:658-666
12. Menzin J, Lang KM, Friedman M et al. Excess mortality, length of stay, and costs associated with serious fungal infections among elderly cancer patients: findings from linked SEER-Medicare data. Value Health. 2005; 8:140-148 (Pubitemid 40525375)
13. Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosis-related hospitalizations in the United States. Clin Infect Dis. 2000; 31:1524-1528 [Erratum, Clin Infect Dis. 2001; 32:673.]
14. Simonsen L, Conn LA, Pinner RW et al. Trends in infectious disease hospitalizations in the United States, 1980-1994. Arch Intern Med. 1998; 158:1923-1928
15. Fraser DW, Ward JI, Ajello L et al. Aspergillosis and other systemic mycoses. The growing problem. JAMA. 1979; 242:1631-5.
16. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis. 2001; 33:1692-1696 (Pubitemid 33044535)
17. Morgan J, Meltzer MI, Plikaytis BD et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol. 2005; 26:540-547 [Erratum, Infect Control Hosp Epidemiol. 2005; 26:675.]
18. Zaoutis TE, Argon J, Chu J et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005; 41:1232-1239 (Pubitemid 41532664)
19. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project - overview of the Nationwide Inpatient Sample (NIS). www.hcup-us.ahrq.gov/nisoverview.jsp (accessed 2009 Jun 25).
20. Healthcare Cost and Utilization Project. Clinical Classifications Software (CCS) for ICD-9-CM. www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp (accessed 2007 Feb 21).
21. U.S. Census Bureau. American FactFinder: population finder. http://factfinder.census.gov/servlet/SAFFPopulation?-submenuId= population-0&-sse=on (accessed 2007 Feb 1).
22. Chang DC, Burwell LA, Lyon GM et al. Comparison of the use of administrative data and an active system for surveillance of invasive aspergillosis. Infect Control Hosp Epidemiol. 2008; 29:25-30.
23. Petrikkos G, Skiada A. Recent advances in antifungal chemotherapy. Int J Antimicrob Agents. 2007; 30:108-117
24. Dodds Ashley ES. Treatment options for invasive fungal infections. Pharmacotherapy. 2006; 26:55S-60S.
25. Rubin ZA, Somani J. New options for the treatment of invasive fungal infections. Semin Oncol. 2004; 31:91-98 (Pubitemid 38609800)
26. Sullivan KM, Dykewicz CA, Longworth DL et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology Am Soc Hematol Educ Program. 2001:392-421.